Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$2,719 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.5 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
4.8
Industry P/E
--
EV/EBITDA
-3.6
Div. Yield
0 %
Debt to Equity
0.1
Book Value
$9.4
EPS
$-4.7
Face value
--
Shares outstanding
71,355,667
CFO
$-228.58 Mln
EBITDA
$-290.88 Mln
Net Profit
$-282.92 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Vera Therapeutics Inc. Class A (VERA)
| -20.0 | -0.7 | -20.0 | 68.6 | 73.5 | -- | -- |
|
BSE Sensex*
| -15.3 | -11.8 | -15.8 | -5.7 | 6.7 | 7.5 | 11.0 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Vera Therapeutics Inc. Class A (VERA)
| 19.7 | 172.7 | -20.5 | -27.6 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Vera Therapeutics Inc. Class A (VERA)
|
40.5 | 2,718.7 | 0.0 | -299.6 | -- | -50.7 | -- | 4.8 |
| 62.9 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 66.6 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 44.0 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 91.2 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 65.4 | 7,360.8 | 1,396.6 | 316.9 | 59.8 | 153.6 | 24.3 | 153.4 | |
| 7.1 | 6,847.2 | 113.3 | -351.4 | -211.0 | 71.1 | -- | 0.0 | |
| 529.8 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 489.5 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 319.3 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion... protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California. Address: 2000 Sierra Point Parkway, Brisbane, CA, United States, 94005 Read more
Founder, President, CEO & Director
Dr. Marshall W. Fordyce M.D.
Founder, President, CEO & Director
Dr. Marshall W. Fordyce M.D.
Headquarters
Brisbane, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Vera Therapeutics Inc Class A (VERA) is $40.50 (NASDAQ) as of 01-Apr-2026 16:01 EDT. Vera Therapeutics Inc Class A (VERA) has given a return of 73.46% in the last 3 years.
Since, TTM earnings of Vera Therapeutics Inc Class A (VERA) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-10.82
|
5.36
|
|
2024
|
-15.29
|
4.03
|
|
2023
|
-6.89
|
6.50
|
|
2022
|
-5.87
|
6.79
|
|
2021
|
-10.65
|
4.99
|
The 52-week high and low of Vera Therapeutics Inc Class A (VERA) are Rs 56.05 and Rs 18.53 as of 02-Apr-2026.
Vera Therapeutics Inc Class A (VERA) has a market capitalisation of $ 2,719 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Vera Therapeutics Inc Class A (VERA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.27
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.